Marked improvement in the success rate of medical management of early pregnancy failure following the implementation of a novel institutional protocol and treatment guidelines: a follow-up study

V. Colleselli 1 · T. Nell 2 · T. Bartosik 2 · C. Brunner 1 · A. Ciresa-Koenig 1 · L. Wildt 2 · C. Marth 1 · B. Seeber 2

Received: 12 June 2016 / Accepted: 9 August 2016 / Published online: 23 August 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract

Purpose To analyze the success rate, time to passage of tissue and subjective patient experience of a newly implemented protocol for medical management of early pregnancy failure (EPF) over a 2-year period.

Methods A retrospective chart review of all patients with early pregnancy failure primarily opting for medical management was performed. 200 mg mifepristone were administered orally, followed by a single vaginal dose of 800 mcg misoprostol after 36–48 h. We followed-up with our patients using a written questionnaire.

Results 167 women were included in the present study. We observed an overall success rate of 92 %, defined as no need for surgical management after medication administration. We could not identify predictive values for success in a multivariate regression analysis. Most patients (84 %) passed tissue within 6 h after misoprostol administration. The protocol was well tolerated with a low incidence of side effects. Pain was managed well with sufficient analgesics. Responders to the questionnaire felt adequately informed prior to treatment and rated their overall experience as positive.

Conclusion The adaption of the institutional medical protocol resulted in a marked improvement of success rate when compared to the previously used protocol (92 vs. 61 %). We credit this increase to the adjusted medication schema as well as to targeted physician education on the expected course and interpretation of outcome measures. Our results underscore that the medical management of EPF is a safe and effective alternative to surgical evacuation in the clinical setting.

Keywords Early pregnancy failure · Medical management · Mifepristone · Misoprostol

Introduction

Early pregnancy failure (EPF) is a common pregnancy complication with approximately 25 % of pregnancies ending in miscarriage and with 1 in 4 women experiencing this problem during her reproductive lifespan [1–3]. With the routine use of ultrasound, these pregnancy failures are often diagnosed prior to the onset of any symptoms, such as bleeding or cramping, and have been therefore termed “missed abortions”. Improvements in ultrasound technology have further enabled the subclassification of asymptomatic EPF into intrauterine embryonic/fetal demise (IUED/IUFD) and anembryonic gestation (“blighted ovum”). In contrast, women with inevitable abortion, incomplete abortion and completed abortion experience cervical dilation, cramping, and bleeding during the passage of tissue that ends in miscarriage [4, 5].

Considering the psychological and physical burden of experiencing a pregnancy failure, it is important to be able to offer patients effective, timely, and safe management [6, 7]. Upon the definitive diagnosis of EPF, the following three treatment options may be considered: (1) expectant management with follow-up; (2) surgical management with pregnancy evacuation [cervical dilation followed by...
suction or blunt curettage (D&C)]; or (3) medical management using misoprostol or a combination of mifepristone and misoprostol to induce uterine evacuation [4, 5].

Historically, surgical management was the mainstay of management, offering prompt uterine evacuation with a high rate of success of over 95%. More recently, medical management has become an established alternative option for patients wishing to avoid surgery and its associated operative risks, such as uterine perforation, endometritis, injury to the cervix, and Asherman’s syndrome, as well as potential anesthesia-related complications [4, 5, 8–11]. Medical management of EPF is routinely carried out with the prostaglandin E1 analogue Misoprostol which induces cervical dilation and uterine contractions, inducing the vaginal expulsion of the failed pregnancy. Some, but not all, clinicians administer mifepristone, a competitive progesterone antagonist, 24–48 h prior to misoprostol administration to improve the success rate by disrupting the progesterone-mediated trophoblast-decidua interaction. Corresponding study results are contradictory. While some studies show promising results exceeding a success rate of 85–90% with coexistent mifepristone use, others have found no additional benefit whether a dose of 200 mg or 600 mg is given, at the cost of increased expense [10, 12–17]. Unlike its beneficial use in elective terminations of viable pregnancies (elective abortions), mifepristone may have limited usefulness in failed pregnancy which have lower progesterone levels [18–21].

The overall success rate of medical management quoted in the literature is highly variable, ranging from 66–83% in clinical practice and even as high as 95% in small research studies, as summarized in Table 1. In our previous publication of the success rate in routine clinical practice in our university clinic, we found a disappointingly low rate of only 61% [14]. The reason for this discrepancy is likely due to the great institutional variability in the medications, their dosages, routes, and time intervals of administration used for treatment. In addition, as shown in Table 1, the definition of successful treatment varies greatly from study to study, and has been defined as no presence of gestational sac on ultrasound, termination of vaginal bleeding, or by endometrial thickness on ultrasound [5, 22–25]. Finally, the more experienced clinician is in the use of medical management, the more comfortable he/she may be with expectantly managing the patient with heavy or prolonged bleeding post-medication administration. Less experienced

| Study               | Design      | Mifepristone | Misoprostol                                                                 | Success | Definition of success                                                                 |
|---------------------|-------------|--------------|-----------------------------------------------------------------------------|---------|--------------------------------------------------------------------------------------|
| Colleselli et al. [14] | Retros. | 600 mg orally | 400 mcg orally, followed by 400 mcg vaginally in 4 h intervals, max. 2400 mcg | 61 %    | Not standardized, Dependent on treating physician                                    |
| Van den Berg et al [10] | Retros. | Group 1: 200 mg orally | Group 1: after 36 h 800 μg vaginally, Group 2: 2 doses of 800 μg vaginally, time interval 24 h | Group 1: 67 %, Group 2: 55 % (statistically significant) | Clinical signs, empty uterine cavity on ultrasound or hysteroscopy, absence of products of conception in histology |
| Barcelo et al. [27] | Retros. | – | 2 doses of 600 μg or 800 μg vaginally, time interval 24 h | 88/91 % | No gestational sac on ultrasound                                                     |
| Kollitz et al. [13] | Retros. | 200 mg orally | After 24 h 800 μg vaginally, if indicated additional dose after 7 days | 80/83 % | No presence of gestational sac and endometrial thickness <30 mm on ultrasound         |
| Stockheim et al. [16] | Prosp. | Group 1: 600 mg orally | Group 1: after 48 h 800 μg orally, Group 2: 2 doses of 800 μg orally, time interval 48 h | Group 1: 66 %, Group 2: 74 % | No need for surgical intervention                                                   |
| Schreiber et al. [12] | Prosp. | 200 mg orally | After 24 h 800 μg vaginally, if indicated additional dose after 7 days | 90/93 % | Expulsion of gestational sac, no need for D&C                                       |
| Zhang et al. [30] | Prosp. | – | 800 μg vaginally, if indicated additional dose after 48 h | 71/84 % | no need for surgical intervention within 30 days after initial treatment            |
| Grønlund et al [15] | Prosp. | Group 1: 600 mg orally | 400 μg vaginally, if no bleeding after 2 h à 200 μg additionally (group 1: 48 h after mifepristone) | Group 1: 4 %, Group 2: 7 % | No need for surgical evacuation after medical treatment                             |

Retrosp. retrospective, prosp. prospective

Springer
clinicians may be prompted to intervene too quickly with curettage, thus decreasing the perceived success rate.

We aimed to improve the success of medical management of EPF in our university hospital setting by adopting the most successful evidenced-based medication regimen while limiting costs. In addition, we formally reviewed with the treating physicians, the expected effects of treatment (bleeding pattern and duration, cramping, and pain) as well as the expected post-treatment ultrasound findings and their correct interpretation. Finally, we defined standard operating procedures (SOP) to standardize and optimize the clinical course of treatment and to define the indications for surgical intervention. This treatment algorithm is shown in Fig. 1.

In this study, we retrospectively analyze the success rate of the medical management of EPF in the first 2 years upon the implementation of the above-mentioned changes. In addition, we report the results of a questionnaire sent to the patients who were treated with medical management during this time period which compared the patients’ expectations of treatment (bleeding, pain, and side effects) to their actual experiences and inquired about their willingness to choose this treatment option in the future or to recommend it to a friend.

Materials and methods

The present retrospective study was approved by the institutional ethics committee of the Medical University of Innsbruck. The participants who returned the follow-up questionnaires signed an informed consent.

As summarized in Fig. 1, according to institutional SOPs, all patients diagnosed with a non-viable early pregnancy are presented three options upon diagnosis: (1) expectant management, (2) surgical management by dilation and curettage (D&C), and (3) medical management with mifepristone and misoprostol. All patients primarily opting for medical management receive a single oral dose of 200 mg Mifepristone on an out-patient basis and are subsequently admitted 36–48 h later to our day-inpatient unit. On admission, an ultrasound is performed to confirm the continued presence of the intrauterine EPF, and diclofenac and metogastrone are given intravenously for prevention of pain and nausea, respectively. Subsequently, a single dose of 800 mcg (4 Tablets of 200 mcg each) misoprostol is administered intra-vaginally to the posterior fornix by the treating physician. All patients are monitored for the following 8 h for bleeding and passage of tissue which is recorded in the electronic medical record. They may be administered additional analgesics or antiemetics, as necessary. In a small subset of patients, outside of the defined SOP, an additional dose of 400 mcg Misoprostol was administered buccally when no passage of tissue took place after 6 h of the vaginal dose. Following the suspected passage of the failed pregnancy, or at the latest at 5 pm (closing time of the day-unit), a transvaginal ultrasound is performed to guide further follow-up. If the ultrasound shows no gestational sac present, the endometrial thickness is less than 20 mm, and bleeding is within normal limits, then the patient is discharged and an out-patient follow-up visit is scheduled in 4 weeks’ time. If the gestational sac is still visible and/or the endometrium thickness measures more than 20 mm, and bleeding is within normal limits, then the patient is discharged and scheduled for follow-up in 1 week. At the 1 week appointment, a re-evaluation is performed. If there are sonographic or clinical evidences for ongoing EPF, then the patient can opt for another course of misoprostol, expectant management, or surgical management.

Using admission records, we identified all patients who received medical management for EPF in the 2-year period between March 1, 2013 and February 28, 2015. To be
included, the women had to have a missed abortion ≤12-week gestation (intrauterine embryonic or fetal demise or anembryonic gestation without cervical dilation or heavy bleeding). Exclusion criteria included multiple gestation, pregnancy with an IUD in place, gestational age >13 weeks by ultrasound, and the diagnosis of inevitable, incomplete, and complete miscarriage. Patients’ charts and electronic records were retrospectively abstracted to collect clinical and ultrasound data at initial presentation and the clinical course following misoprostol administration, focusing on the time to passage of tissue, amount of bleeding, and medications’ administered and documented side effects. Relevant previous obstetric, gynecologic, and medical history were recorded. Treatment success was defined as no surgical intervention after initiation of medical treatment. We calculated the overall success rate for all women, and according to gestational age (≤9 vs. >10), and diagnosis (anembryonic gestation vs. IUED/IUFD). Logistic regression analyses were performed to evaluate for pre-selected predictive factors of success, using the independent variables age, body mass index (BMI), parity, gestational age (GA), and diagnosis.

We compared the outcomes of the present study to those we previously reported from a retrospective review of cases between 2006 and February 2012 prior to the establishment of the current SOPs. We used the student’s t test or Mann–Whitney U test to compare parametric and non-parametric outcomes, respectively, and the Chi-square test to compare binomial outcomes. Analyses were performed using PASW Statistics for Windows, Version 18.0. Chicago: SPSS Inc.

Finally, we followed-up with our patients by mailing each of the women a questionnaire to be filled out and returned in an envelope provided. The questions in this questionnaire asked whether the treatment experience met the women’s expectations in terms of amount and duration of bleeding, amount of pain as well as asked how they rated the overall experience and whether they would choose this treatment method again and/or recommend it to a friend.

### Results

We identified 167 patients who met the inclusion criteria and were included in this study. Patient characteristics are shown in Table 2 and are similar to those of the women who made up the study population reported in our previous publication [14].

153 of 167 women were successfully treated with medical management for a cumulative success rate of 92% (n = 69/79 or 81% in the first year and n = 84/88 or 97% in the second year). Subgroup analyses by gestational age (≤9 weeks, >10 weeks) and diagnosis (IUED/IUFD vs. anembryonic gestation) showed no significant difference in successful management (GA by LMP—91 vs. 88%, p = 0.498; GA by ultrasound—89 vs. 82%, p = 0.468; diagnosis—87 vs. 97%, p = 0.081).

To identify possible predictive factors for success, we performed a multivariate regression analysis. None of the pre-selected independent variables were able to predict successful treatment (Table 3).

Since this is a retrospective evaluation of routine clinical practice, a small number of women were treated outside of the standardized protocol by the treating physician. Namely, in the absence of passage of tissue within 6 h of vaginal misoprostol administration, 26 patients (16%) received an additional dose of 400 mcg misoprostol buccally. Of these women, 15 passed tissue within the following 2–3 h, while 11 still had no passage of tissue.

In 92 cases, the exact time of the first passage of tissue after administration of misoprostol was documented. In 77 of these women (84%), it occurred within 6 h after

### Table 2 Patient characteristics

| Parameter                  | March 2013–February 2015 N = 167 | Colleselli et al. [14] N = 168 | p    |
|----------------------------|---------------------------------|--------------------------------|------|
| Age (years)                | 33.2 ± 6.0                      | 32.7 ± 6.6                     | 0.474|
| BMI                        | 23.6 ± 4.2                      | 22.7 ± 3.7                     | 0.085|
| Gravidity                  | –                               | 2 (1–9)                       | –    |
| Parity                     | –                               | 1 (0–5)                       | –    |
| GA by LMP (weeks)          | 10.0 ± 1.6                      | 10.1 ± 2.1                    | 0.756|
| GA by ultrasound (weeks)   | 7.8 ± 1.5                       | 8.1 ± 1.8                     | 0.343|
| Time to surgery after misoprostol (days) | 26.1 ± 19.3 | 5.3 ± 9.6 | <0.001* |
| Expulsion time after administration of misoprostol (hours) | 4.7 ± 1.8 | 5.5 (1–34) | <0.001* |

* Statistically significant
misoprostol administration, with a median of 4.3 h. In the remaining 15 women, it was still within 9 h of medication administration, since these women were discharged without a gestational sac. Overall, the time to passage of tissue was statistically significantly shorter than with our previous protocol when the median time was 5.5 h. In contrast, the time to surgical intervention was statistically significantly longer with the revised protocol. In the few women who needed surgical evacuation, this was performed on average 26 days after medication administration, in comparison with just 5 days post-treatment between 2006 and 2012.

In Fig. 2, we show the detailed outcomes for the patients. 23 patients were discharged with a visible gestational sac or endometrial lining >20 mm on ultrasound. Only 3 of these women required a surgical intervention (curettage) to be subsequently performed. In 2 of these women this was due to persistent bleeding and in 1 of the women due to continued presence of the gestational sac on ultrasound. In none of these women were the surgical intervention emergent.

Of the 143 women discharged without a gestational sac and Endometrium <20 mm (presumed to be a completed abortion), ten nonetheless underwent surgical intervention. The indications for curettage in these women were suspected retained products of conception on ultrasound in eight cases and persistent bleeding in two cases. None of these interventions were performed on an emergency basis. None of these women opted for a repeat treatment with misoprostol. For the total of 13 women who needed curettage, the procedure was performed between 0 and 57 days after the administration of misoprostol, median 22.5 days. In 50 % of women, chorionic villi were obtained, confirming retained products of conception. One woman required a blood transfusion post-surgery for heavy intraoperative bleeding. No blood transfusion was administered after medical management alone.

The overall rate of side effects was low. The most common side effects reported were nausea (10 %), vomiting (5 %), diarrhea (4 %), cramping, and pain (59 %); however, most patients only experienced mild pain (90 %).

### Table 3: Multivariate regression analysis, independent variable = success

| Parameter          | $p$  |
|--------------------|------|
| Diagnosis$^a$      | 0.253|
| Age$^b$            | 0.449|
| BMI$^c$            | 0.860|
| Parity$^d$         | 0.811|
| GA by LMP$^e$      | 0.564|

$^a$ Diagnosis: IUED/IUFD vs. anembryonic gestation  
$^b$ Age (years)-groups: <24, 25–64, 35–39, >40  
$^c$ BMI groups: <18, 18–25, >25  
$^d$ Parity: 0, ≥1  
$^e$ GA by LMP (weeks): ≤9, ≥10
To gain insight into the subjective experience of our patients, we sent all medically treated patients a questionnaire together with a pre-paid return-addressed envelope, 62 of which were returned (return rate 37 %). 92 % of questionnaire participants felt that they received sufficient written and oral information prior to treatment. Nonetheless, fewer than half of the women reported the duration and amount of bleeding and pain to be consistent with expectations. In 27–34 % of responders, these parameters were more severe than expected, in the remaining responders less than expected, as shown in Table 4. Despite these results, 65 % of responders evaluated the overall experience as positive, with only 15 % negative and 21 % neutral ratings. 63 % of responders would opt for medical therapy again in the case of another EPF, while only 10 % would primarily choose surgery, and the remainder were not sure. Positive aspects of medical management most frequently noted were avoidance of a surgical procedure (76 %), care and support of staff (66 %), short treatment duration (57 %), and well-managed pain control (44 %). We saw an improvement in responses when comparing the first year to the second year of protocol implementation, as shown in Table 5. Due to only five questionnaires being returned from women with unsuccessful treatment, we were unable to make meaningful comparisons of their treatment evaluations compared to those treated successfully.

### Table 4 Respondents’ expectations

|                        | Consistent with expectations (%) | More than expected (%) | Less than expected (%) |
|------------------------|---------------------------------|------------------------|------------------------|
| Duration of bleeding   | 44                              | 27                     | 27                     |
| Amount of bleeding     | 48                              | 34                     | 18                     |
| Pain                   | 40                              | 31                     | 29                     |

### Table 5 Questionnaire—comparison of year one and two

|                        | March 2013–February 2014 N = 32 (%) | March 2014–February 2015 N = 30 (%) |
|------------------------|-------------------------------------|-------------------------------------|
| Sufficient information | 84                                  | 100                                 |
| Duration of bleeding   | 38                                  | 50                                  |
| Amount of bleeding     | 44                                  | 53                                  |
| Pain                   | 34                                  | 47                                  |
| Choose medical treatment again | 60                                  | 67                                  |
| Recommend medical treatment to a friend | 69                                  | 87                                  |

**Discussion**

The introduction of a new institutional protocol for the medical management of EPF resulted in a marked improvement in the success rate to 92 %, compared to the previous success of 61 % [14]. This high success rate is comparable to that reported in interventional studies under research protocols summarized in Table 1. For this improvement, we credit the use of an evidence-based medication schema (200 mg mifepristone orally followed by a single dose of 800 mcg misoprostol vaginally), targeted physician education, as well as the adoption of SOPs. The aim of the SOPs was to standardize the treatment algorithm and to aid the clinician in interpreting clinical signs and ultrasound results to plan follow-up accordingly.

Most women expelled the failed pregnancy during their stay in our day clinic and within only a few hours after medication administration. These data are important in accurately counseling women regarding their expectations. Although medical management can be safely performed as an out-patient treatment at home, we feel it is reassuring for the women to be monitored for bleeding and to be offered adequate pain management [26, 27].

Of the 23 women who did not expel the tissue during the first day of monitoring, the great majority (87 %) did so within the following week. This is consistent with previous studies and supports the recommendation to allow up to 7 days before subsequent re-evaluation and additional treatment [11]. This is a safe management strategy, supported by our findings that none of the women required an emergent surgical intervention due to heavy bleeding.

The most frequent indication for surgical intervention was persistent vaginal bleeding despite previous passage of the gestational sac. Very few women had sonographic evidence of persistent products of conception as the indication for surgery. Histological evaluation confirmed the presence if intrauterine chorionic villi in only half of the curettage specimens. Thus, it is impossible to know whether some or most of these women would have spontaneously ceased bleeding without surgical intervention. Previous studies have shown that bleeding patterns following medical management of EPF can be quite variable, but prolonged bleeding exceeding 20 days is not uncommon [28]. In fact, recent management strategies call for a longer time until intervention, waiting for up to 4–6 weeks [29].

It is reassuring that this combined protocol of mifepristone and misoprostol was well tolerated with a paucity of gastrointestinal side effects, especially when compared to other studies [30]. This may be partly due to the prophylactic administration of antiemetics prior to misoprostol administration.
Nonetheless, facing a non-viable pregnancy is psychologically difficult for affected women. Eligible women should, therefore, be counseled appropriately to enhance their understanding and expectations of treatment and psychological counseling should be offered routinely.

The study is limited by its retrospective design and lack of randomization. Therefore, we cannot evaluate whether the women who chose first-line medical management differ from those who prefer surgical treatment from the outset or from those who choose expectant management. However, due to strong patient preferences for which treatment they choose, a randomized study of medical vs. surgical intervention will likely never be able to be conducted. The study was conducted at a single university-based hospital, which may potentially limit the generalizability of the results to other treatment settings.

To further improve counseling for medical treatment, we designed a questionnaire to investigate patients’ experiences and satisfaction with the present protocol. Although a detailed written informed consent and information sheet is provided prior to treatment begin, one which the responders deemed adequately informative, their expectations regarding bleeding and pain were nonetheless incorrect in more than half of cases. This highlights the importance of an individual discussion with each patient. We did see a distinct improvement in the accuracy of expectations when comparing the first year to the second year following the implantation of the protocol. We believe that this improvement might be attributed to more clinical experience and increasing familiarity with the SOPs, translating into more accurate information given to the patient.

Surgical treatment of EPF is associated with the risk factors of perforation, bleeding, anesthesia, and subsequent Asherman’s syndrome [8]. In addition, preliminary evidence shows that surgical management, especially with dilation of the cervix and curettage, might have adverse effects on future pregnancies [31–33]. Therefore, it is especially important to be able to offer highly effective medical management as an alternative to operative intervention. Medical management needs to be performed using evidence-based protocols by physicians trained in the expected outcomes, especially regarding bleeding and pain, and in the interpretation of ultrasound findings so as not to intervene unnecessarily.

In a standard gamble study, Graziosi et al. showed that when faced with the diagnosis of EPF, women prefer medical management to surgical when the success rate of the former exceeds 65% [7]. We were able to far exceed this success rate in our routine clinical practice and without adherence to a strict research protocol. In conclusion, our results support the use of medical management as a valuable non-invasive alternative to surgery in routine clinical practice. Our findings, furthermore, underscore the importance of formally educating caregivers regarding the expected findings, expected pain, patterns of bleeding following administration of medications and ultrasound interpretation to optimize treatment success.

Acknowledgments Open access funding provided by University of Innsbruck and Medical University of Innsbruck.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflicts of interest.

Funding The study did not have external funding.

Ethics/informed consent The study was approved by the Ethics Committee of the Medical University of Innsbruck. All individual participants included in the study gave their informed consent for the prospective portion of the study. All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Casterline JB (1989) Collecting data on pregnancy loss: a review of evidence from the World Fertility Survey. Stud Fam Plann 20(2):81–95
2. Jones RK, Kost K (2007) Underreporting of induced and spontaneous abortion in the United States: an analysis of the 2002 National Survey of Family Growth. Stud Fam Plann 38(3):187–197
3. Bulletti C, Flamigni C, Giacomucci E (1996) Reproductive failure due to spontaneous abortion and recurrent miscarriage. Hum Reprod Updat 2(2):118–136
4. Chen BA, Creinin MD (2007) Contemporary management of early pregnancy failure. Clin Obstet Gynecol 50(1):67–88
5. Chen B, Creinin M (2008) Medical management of early pregnancy failure: efficacy. Semin Reprod Med 26(05):411–422
6. Lee DT, Cheung LP, Haines CJ, Chan KP, Chung TK (2001) A comparison of the psychologic impact and client satisfaction of surgical treatment with medical treatment of spontaneous abortion: a randomized controlled trial. Am J Obstet Gynecol 185(4):953–958
7. Graziosi GC, Bruinse HW, Reuwer PJ, Mol BW (2006) Women’s preferences for misoprostol in case of early pregnancy failure. Eur J Obstet Gynecol Reprod Biol 124(2):184–186
8. Sotiriadis A, Makrydimas G, Papatheodorou S, Ioannidis JPA (2005) Expectant, medical, or surgical management of first-trimester miscarriage: a meta-analysis. Obstet Gynecol 105(5 Pt 1):1104–1113
9. Creinin MD, Schwartz JL, Guido RS, Pymar HC (2001) Early pregnancy failure-current management concepts. Obstet Gynecol Surv 56(2):105–113
10. van den Berg J, Gordon BBM, Snijders MPML, Vandenbussche FPHA, Coppus SFPJ (2015) The added value of mifepristone to non-surgical treatment regimens for uterine evacuation in case of early pregnancy failure: a systematic review of the literature. Eur J Obstet Gynecol Reprod Biol 195:18–26

11. Dempsey A, Davis A (2008) Medical management of early pregnancy failure: how to treat and what to expect. Semin Reprod Med 26(05):401–410

12. Schreiber CA, Creinin MD, Reeves MF, Harwood BJ (2006) Mifepristone and misoprostol for the treatment of early pregnancy failure: a pilot clinical trial. Contraception 74(6):458–462

13. Kollitz KM, Meyn LA, Lohr PA, Creinin MD (2011) Mifepristone and misoprostol for early pregnancy failure: a cohort analysis. Am J Obstet Gynecol 204(5):386.e1–386.e6

14. Colleselli V, Schreiber CA, D’Costa E, Mangesius S, Wildt L, Seeber BE (2014) Medical management of early pregnancy failure (EPF): a retrospective analysis of a combined protocol of mifepristone and misoprostol used in clinical practice. Arch Gynecol Obstet 289(6):1341–1345

15. Grønlund A, Grønlund L, Clevin L, Andersen B, Palmgren N, Lidegaard O (2002) Management of missed abortion: comparison of medical treatment with either mifepristone + misoprostol or misoprostol alone with surgical evacuation. A multi-center trial in Copenhagen county, Denmark. Acta Obstet Gynecol Scand 81(11):1060–1065

16. Stockheim D, Machttinger R, Wiser A, Dulitzky M, Soriano D, Goldenberg M et al (2006) A randomized prospective study of misoprostol or mifepristone followed by misoprostol when needed for the treatment of women with early pregnancy failure. Fertil Steril 86(4):956–960

17. Gemzell-Danielsson K, Bygdeman M, Aronsson A (2006) Studies on uterine contractility following mifepristone and various routes of misoprostol. Contraception 74(1):31–35

18. Hamoda H, Ashok PW, Flett GMM, Templeton A (2005) A randomised controlled trial of misoprostol in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation. BJOG 112(8):1102–1108

19. Ngoc NTN, Shochet T, Raghavan S, Blum J, Nga NTB, Minh NTH et al (2011) Mifepristone and misoprostol compared with misoprostol alone for second-trimester abortion: a randomized controlled trial. Obstet Gynecol 118(3):601–608

20. Goel A, Mittal S, Taneja BK, Singal N, Attri S (2011) Simultaneous administration of mifepristone and misoprostol for early termination of pregnancy: a randomized controlled trial. Arch Gynecol Obstet 283(6):1409–1413

21. Chen MJ, Creinin MD (2015) Mifepristone with buccal misoprostol for medical abortion: a systematic review. Obstet Gynecol 126(1):12–21

22. Grossman D, Grindlay K (2011) Alternatives to ultrasound for follow-up after medication abortion: a systematic review. Contraception 83(6):504–510

23. Creinin MD, Harwood B, Guido RS, Fox MC, Zhang J, NICHD Management of Early Pregnancy Failure Trial (2004) Endometrial thickness after misoprostol use for early pregnancy failure. Int J Gynaecol Obstet 86(1):22–26

24. Reeves MF, Lohr PA, Harwood BJ, Creinin MD (2008) Ultrasonographic endometrial thickness after medical and surgical management of early pregnancy failure. Obstet Gynecol 111(1):106–112

25. Reeves MF, Fox MC, Lohr PA, Creinin MD (2009) Endometrial thickness following medical abortion is not predictive of subsequent surgical intervention. Ultrasound Obstet Gynecol 34(1):104–109

26. Gold M, Chong E (2015) If we can do it for misoprostol, why not for mifepristone? The case for taking mifepristone out of the office in medical abortion. Contraception 92(3):194–196

27. Barceló F, De Paco C, López-Espín JJ, Silva Y, Abad L, Parrilla JJ (2012) The management of missed miscarriage in an outpatient setting: 800 versus 600 μg of vaginal misoprostol. Aust N Z J Obstet Gynaecol 52(1):39–43

28. Davis A, Westhoff C, De Nonno L (2000) Bleeding patterns after early abortion with mifepristone and misoprostol or manual vacuum aspiration. J Am Med Womens Assoc 55(3 Suppl):141–144

29. Amer-Alshiek J, Shiekh O, Agmon A, Grisaru D (2015) What is the right timing for ultrasound evaluation after pregnancy termination with mifepristone? Eur J Obstet Gynecol Reprod Biol 189:24–26

30. Zhang J, Gilles JM, Barnhart K, Creinin MD, Westhoff C, Frederick MM (2005) A comparison of medical management with misoprostol and surgical management for early pregnancy failure. N Engl J Med 353(8):761–769

31. McCarthy FP, Khashan AS, North RA, Rahma MB, Walker JJ, Baker PN et al (2013) Pregnancy loss managed by cervical dilatation and curettage increases the risk of spontaneous preterm birth. Hum Reprod 28(12):3197–3206

32. Lemmers M, Verschoor MAC, Hooker AB, Opmeer BC, Limjens J, Huirne JA et al (2016) Dilatation and curettage increases the risk of subsequent preterm birth: a systematic review and meta-analysis. Hum Reprod 31(1):34–45

33. Saccone G, Perlera L, Berghella V (2015) Prior uterine evacuation of pregnancy as independent risk factor for preterm birth: a systematic review and meta-analysis. Am J Obstet Gynecol. doi:10.1016/j.ajog.2015.12.044. (Epub ahead of print)